Erlotinib Hydrochloride Tablet, Film Coated
Product Images NDC 72205-080

11 FDA label images from Novadoz Pharmaceuticals Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Erlotinib Hydrochloride (NDC 72205-080). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

100-mg-carton-label (100 mg Carton Label)

100-mg-carton-label (100 mg Carton Label)
Packaging label for Erlotinib Tablets 100 mg, film-coated oral tablets. The label shows a quantity of 30 tablets and is marked Rx Only. It includes NDC 72205-081-30 and is labeled by Novadoz Pharmaceuticals LLC. Storage instructions and manufacturer information for MSN Laboratories Private Limited, India, are also presented along with barcodes and dosing guidance references.*
FDA Label Image

100-mg-cntr-label (100 mg Cntr Label)

100-mg-cntr-label (100 mg Cntr Label)
Erlotinib Hydrochloride 100 mg film-coated tablets packaging label showing 30 tablets per package. The label states prescription use only, NDC 72205-081-30, manufacturer MSN Laboratories Private Limited, and distributor Novadoz Pharmaceuticals LLC. Storage instructions and dosage comments are included, along with a barcode and contact information for Novadoz Pharmaceuticals.*
FDA Label Image

150-mg-carton-label (150 mg Carton Label)

150-mg-carton-label (150 mg Carton Label)
Packaging label for Erlotinib Tablets 150 mg by Novadoz Pharmaceuticals LLC. The film-coated tablets come in a pack of 30 and are for oral use. The label displays the NDC 72205-082-30, Rx only, and storage instructions. Manufactured by MSN Laboratories Private Limited, Telangana, India, and distributed by Novadoz Pharmaceuticals in Piscataway, NJ.*
FDA Label Image

150-mg-cntr-label (150 mg Cntr Label)

150-mg-cntr-label (150 mg Cntr Label)
Label for Erlotinib Tablets 150 mg film-coated tablets by Novadoz Pharmaceuticals LLC. The label indicates 30 tablets per package, with storage instructions and manufacturing details by MSN Laboratories Private Limited in India. The NDC is 72205-082-30.*
FDA Label Image

25-mg-carton-label (25 mg Carton Label)

25-mg-carton-label (25 mg Carton Label)
Packaging label for Erlotinib Tablets 25 mg film-coated tablets by Novadoz Pharmaceuticals LLC. The label indicates 30 tablets per package, with storage instructions to keep at 25°C (77°F) with allowed excursions between 15° to 30°C. It includes the NDC code 72205-080-30 and manufacturer information listing MSN Laboratories Private Limited in India.*
FDA Label Image

25-mg-cntr-label (25 mg Cntr Label)

25-mg-cntr-label (25 mg Cntr Label)
Label for Erlotinib Tablets 25 mg, film-coated, oral tablets. The label indicates a package of 30 tablets and states it is Rx only. It includes storage instructions, manufacturer (MSN Laboratories Private Limited, India), and distributor information (Novadoz Pharmaceuticals LLC, Piscataway, NJ). The label features a barcode and the Novadoz logo.*
FDA Label Image

Srt (Erlotinib Structure)

Srt (Erlotinib Structure)
Chemical structure of Erlotinib Hydrochloride showing the molecular arrangement including aromatic rings, nitrogen atoms in the heterocyclic system, methoxyethoxy groups, an alkyne functional group, and the hydrochloride salt.*
FDA Label Image

Fig-1 (Figure 1)

Fig-1 (Figure 1)
A Kaplan-Meier plot showing progression-free survival probability over time in months. Two curves compare patients treated with chemotherapy versus Erlotinib, depicting number of patients at risk at various time points up to 42 months.*
FDA Label Image

Fig-2 (Figure 2)

Fig-2 (Figure 2)
A survival probability Kaplan-Meier curve comparing overall survival (in months) between two groups: Placebo and Erlotinib. The vertical axis represents survival probability from 0 to 1, while the horizontal axis shows time in months from 0 to 36. Below the chart, a table shows the number of patients at risk at various time points for each group, with counts decreasing over time for both Placebo and Erlotinib cohorts.*
FDA Label Image

Fig-3 (Figure 3)

Fig-3 (Figure 3)
A Kaplan-Meier survival curve illustrating overall survival probability over time (in months) comparing Erlotinib versus placebo. The graph plots survival probability on the vertical axis and overall survival in months on the horizontal axis, with patient numbers at risk listed below for both placebo and Erlotinib groups at various time points up to 27 months.*
FDA Label Image

Fig-4 (Figure 4)

Fig-4 (Figure 4)
A Kaplan-Meier survival curve depicting overall survival probability over months for patients treated with Erlotinib compared to placebo. The chart includes patient risk numbers at various time points for both treatment groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.